Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery
25 avr. 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution
24 mars 2022 03h00 HE
|
Sosei Group Corporation
New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities‘Venture-like’ capital allocation approach to focus pipeline...
ORION BIOTECHNOLOGY PRESENTING NEW DATA AT THE GPCR DRUG DISCOVERY SUMMIT
22 mars 2022 09h07 HE
|
Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, March 22, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today...
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2021
10 févr. 2022 03h09 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Sosei Group Corporation Proposes Changes to its Leadership Team as Part of Succession Plan to Drive the Company Through the Next Stage of its Evolution
01 févr. 2022 05h12 HE
|
Sosei Group Corporation
Mr. Chris Cargill nominated for appointment as new Representative Executive Officer, President and Chief Executive OfficerMr. Shinichi Tamura will become Chairman of the Board, as a DirectorMs. Miwa...
Sosei Heptares Webinar Presentation for FY2021 Financial Results
21 janv. 2022 05h29 HE
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights...
Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases
06 janv. 2022 05h07 HE
|
Sosei Group Corporation
Research agreement combines Verily’s proprietary Immune Profiler platform with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform and structure-based drug design capabilities ...
Sosei Heptares to present at 40th Annual J.P. Morgan Healthcare Conference
28 déc. 2021 01h30 HE
|
Sosei Group Corporation
TOKYO, Japan and LONDON, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 40th...
Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
23 déc. 2021 18h05 HE
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces that in connection with the Collaboration and...
Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration
06 juil. 2021 08h10 HE
|
InveniAI LLC
Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early...